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doi:10.1016/j.jds.2012.05.003Abstract Background/purpose: The aim of this study was to evaluate the microbiological and
clinical effects of a chitosan (CH) mouth rinse on plaque inhibition.
Materials and methods: Thirty-six healthy participants were recruited. The following clinical
data were recorded: a plaque index (PI), gingival index (GI), QuickleyeHein plaque index
(QPI), and probing depth (PD). Volunteers were given oral hygiene (OH) instruction and trained
on scaling and professional tooth cleaning (PTC). After the final PTC, volunteers were randomly
allocated into three groups. Group A rinsed with 2% CH, group B rinsed with 0.2% chlorhexidine
digluconate (CHX), and group C rinsed with 2% CHþ 0.2% CHX. Plaque samples were collected
and assayed for Streptococcus mutans, Candida albicans, and enterococci.
Results: After a non-brushing period, the full-mouth PI and QPI values between the CH and
CHXþ CH groups differed significantly. A higher PI score at sampling sites was seen in the CH
group, but no significant differences were observed between groups. The S. mutans and C. albi-
cans levels were statistically significant in each group on Days 0 and 4. Differences of C. albicans
levels between groups were found to be significant; however, no statistical differences were
obtained for S. mutans or enterococci levels among the groups at the various time intervals.
Conclusion: We conclude that further investigations are needed to evaluate the potential value
of CH as an effective antiplaque mouth rinse.
Copyright ª 2012, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.of Periodontology, Faculty of Dentistry, Gazi University, 8. Cad, 84. Sok, Emek, Ankara 06510, Turkey.
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efficacy of a water-soluble form of CH in a mouth rinse toDental plaque is the primary etiologic factor of periodontal
diseases. The removal of bacterial biofilms from tooth
surfaces and plaque control are the main goals of the
prevention and treatment of periodontal diseases.
In addition to mechanical plaque control, the use of
different antiseptic compounds in mouth rinse formulations
can complement or replace mechanical removal. Clinical
studies showed that many of these antimicrobial agents
have inhibitory effects on plaque and gingivitis compared to
negative controls or a placebo, in the absence of tooth
brushing.1,2
In most cases, during phase-I therapy, clinicians recom-
mend that patients use an antimicrobial agent to reduce
plaque accumulation. A variety of antimicrobial agents
have been studied for their ability to prevent dental plaque
formation and inhibit the development of gingivitis.3e7
These microbial agents include metal salts (tin fluoride,
zinc, and copper),8 essential oils,9 phenols,10 fluorides
(sodium fluoride and stannous fluoride),11 bisbiguanides
(chlorhexidine),12 sanguinarine, oxygenating agents etc.
One of the most frequently studied antiplaque agents,
chlorhexidine digluconate (CHX), has been used for more
than three decades for both prevention and therapy of
periodontal diseases owing to its bactericidal and bacte-
riostatic activities.3,13,14 CHX at a 0.2% concentration can
be considered the gold standard for its clinical efficacy in
chemical plaque control.2,15,16 CHX has broad antibacterial
activities, with very low toxicity and a strong affinity for
epithelial tissues and mucous membranes. Despite great
benefits, the application of CHX is limited to short-term use
because of some undesirable side-effects such as brown
staining of the teeth and tongue, an unpleasant taste,
enhanced supragingival calculus formation, and, rarely,
painful desquamations of the oral mucosa, all of which have
led to the search for new formulations.17e19
Chitosan (CH), a natural polysaccharide obtained by
the deacetylation of N-acetyl glucosamine, has received
much more attention as a chemical agent for mouthwashes
that provide clinical benefits for plaque control.20e23
In addition to its favorable properties, such as non-
toxicity, biocompatibility, and biodegradability, CH has an
extended retention time on the oral mucosa. Moreover, CH
itself has an antimicrobial activity.20,24e26 Recent studies
have shown that chitosan has an in vitro antibacterial
effect on Streptococcus mutans, Aggregatibacter actino-
mycetemcomitans, and Porphyromonas gingivalis.25,27,28 It
has also been reported that low-molecular-weight chitosan
prevents the adsorption of S. mutans onto hydroxyapa-
tite.25,27,28 As a bioadhesive polymer, CH provides an
extended retention time on the oral mucosa. Previous
studies have shown that a chlorhexidine (CHX)/CH combi-
nation has a synergistic antiplaque effect, based on the
bioadhesive property of CH.20e24,29,30 Despite these potent
antibacterial and antiplaque properties, the application of
CH as a chemical agent for mouthwashes or ices is limited
because of its insolubility in water and incompatibility with
mouthwash and dentifrice formulations. However, few
studies have shown the antibacterial effects of different
formulations of water-soluble CH in the dental field.26,31This clinical study aimed to investigate the clinical
act against plaque regrowth. Other objectives of this
investigation were to determine its microbiological effects
during a 4-day period of de novo plaque formation and to
compare those with CHX.
Materials and methods
Study population
In total, 36 periodontally healthy participants (16 females
and 20 males; with a mean age of 21.82  0.57 years) were
included in the study. The study was conducted by the
Department of Periodontology at the Dental Faculty of
Gazi University, Ankara, Turkey. This study design was
approved by the Ethical Committee of the Faculty of
Dentistry, Gazi University. After screening for suitability, all
participants who fit the criteria volunteered, received
verbal and written descriptions of the study design, and
signed informed consent forms.
Study design
This randomized clinical study was conducted as a parallel-
group design and was performed in a double-blinded
manner.
Each volunteer had to fulfill the following inclusion
criteria: (i) be in good general health; (ii) have undergone
no antibiotic treatment during the last 6 months; (iii) be
taking no regular medication containing anti-inflammatory
compounds; (iv) not be using tobacco products; (v) have no
regular use of oral antiseptics; (vi) have a minimum of 24
teeth and five teeth in each quadrant; (vii) have no fixed or
removable prostheses, or orthodontic appliances; and (viii)
have no signs of periodontal disease. Those reported to be
allergic to CHX or CH derivates were not allowed to
participate. Participants were comprised of non-smokers.
The study protocol is summarized in Fig. 1. Before the
experimental phase, each participant received oral
professional prophylaxis to remove all plaque, calculus, and
stains from the teeth. This was performed using hand
instruments and rotating brushes with polishing paste, and
was repeated twice a week for a 2-week period. Partici-
pants were provided with a kit containing dental floss,
a standard toothbrush, and conventional toothpaste for
oral hygiene, and were instructed to use it after every meal
until the next visit. Then, participants were asked to
abstain from all mechanical plaque-control measures, but
rinsed with one of three mouth rinses for the following
4 days.
Mouth rinsing was performed twice a day (after break-
fast and in the evening), for 60 seconds with 10 mL of the
assigned product. Rinsing with water for 30 minutes after
this procedure was not allowed. Written instructions
explaining how to use the mouth rinses were provided. The
following mouth rinse preparations were tested: Group 1
used a CHX solution (0.2% chlorhexidine digluconate);
Group 2 used a 2% CH solution; Group 3 used a 0.2% CHX/2%
CH combination.
Figure 1 Study protocol.
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groups described above. All participants were instructed to
refrain from using any other form of oral hygiene and not to
change their dietary habits during the course of the study.
Following the 4-day period of no oral hygiene, participants
resumed optimal mechanical plaque control.
Preparation of the rinse formulations
Water-soluble CH (Protasan UP CL213, Novamatrix, Norway)
with molecular weight of 272 kDa and a deacetylation
degree of 84% was used to prepare the solutions at a 2%
concentration (weight/volume) in distilled water. CHX at
0.2% was incorporated into the CH solutions.24,31 All study
products were blinded. All three mouth rinses were deliv-
ered in brown bottles. The bottles were labeled A, B, and C
by an investigator: bottle A contained 0.2% CHX, bottle B
contained 2% CH, and bottle C contained the 0.2% CHX/2%
CH combination.
Clinical assessments
Whole-mouth recordings in each participant served as
a basis for the clinical periodontal diagnosis. The following
clinical parameters (in sequential order) were recorded at
the baseline, on Day 0, and after 4 days of no oral hygiene:
a plaque index (PI),32 gingival index (GI),33 QuigleyeHein
plaque index (QPI), and probing depth (PD). All clinical
parameters were measured with a GoldmaneFox Williams
probe calibrated in millimeters at six sites per tooth (mesio-
, mid-, and distobuccal, and mesio-, mid-, and distopalatal)
according to the criteria given below.
The PI system score criteria are as follows: 0 indicates no
plaque; 1 indicates a film of plaque adhering to the free
gingival margin and adjacent area of the tooth; 2 indicates
moderate accumulation of soft deposits within the gingival
pocket, or the tooth and gingival margin could be seen with
the naked eye; and 3 indicates an abundance of soft matter
within the gingival pocket and/or on the tooth and gingival
margin.
The GI system score criteria are as follows: 0 indicates
normal gingiva; 1 indicates mild inflammation, a slight
change in color, and slight edema, with no bleeding on
probing; 2 indicates moderate inflammation redness,
edema, and glazing, with bleeding on probing; and 3 indi-
cates severe inflammation, marked redness, edema with
ulceration, and a tendency for spontaneous bleeding.Plaque scoring by the QHI is as follows: 0 indicates no
plaque; 2 indicates separate flecks of plaque at the cervical
margin of the tooth; 3 indicates a thin continuous band of
plaque (up to 1 mm) at the cervical margin of the tooth; 4
indicates a band of plaque wider than 1 mm but covering
less than one-third of the crown of the tooth; 5 indicates
plaque covering at least one-third but less than two-thirds
of the crown of the tooth; and 6 indicates plaque
covering two-thirds or more of the crown of the tooth.
All examinations were performed by a single experi-
enced dental examiner (Duygu Boynuegri) who was blinded
with respect to the mouth rinses. First premolars were used
to evaluate clinical parameters and microbiological
sampling because they were more accessible, and such
sites are less prone to saliva contamination. Third molars
were excluded from the analysis.
Microbiological sampling and analysis
After the sampling sites had been dried and isolated with
cotton rolls, supragingival plaque was sampled from each
patient with a sterile curette. Samples were obtained from
the following surfaces of teeth 14, 24, 34, and 44: mesio-
buccal on Day 0; distobuccal on Day 1; mesiopalatinal on
Day 2; and distopalatinal surfaces on Day 4 to avoid dis-
turbing plaque regrowth. Plaque samples were collected
from different surfaces of each tooth at various time
intervals. The different test sites on each tooth during the
experiment period were used to clarify total bacterial
counts to assess the antibacterial activity of the chitosan
mouth rinse. This selection was made owing to standardi-
zation of clinical and microbiological evaluation of plaque
compositions.
Immediately after removal, plaque samples were pooled
and transferred to an Eppendorf tube containing 1 mL of
reduced transport fluid (RTF). RTF was prepared to trans-
port plaque samples to a microbiology laboratory. The
composition of the RTF/L was as follows: 75 mL of stock
saline solution A (containing 0.6% K2HPO4); 75 mL of stock
saline solution B (containing 1.2% NaCl, 1.2% (NH4)2SO4,
0.6% KH2PO4, and 0.25% MgSO4); 10 mL 0.1 M EDTA; 5 mL 8%
Na2CO3; 20 mL 1% dithiothreitol; and 814 mL distilled water.
This medium was sterilized using a membrane filter. To
collect samples, all transport media were dispensed in 1 mL
samples in Eppendorf tubes. Trypticase yeast-extract
cysteine sucrose bacitracin (TYCSB) selective medium for
S. mutans, Saboraud dextrose agar (SDA) for C. albicans,
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coccus spp. were used to recover microorganisms from the
dental plaque samples. The composition of the TYCSB/L
medium was as follows: 15 g casein; 0.2 g L-cysteine; 5 g
yeast extract; 0.1 g Na2CO3; 1 g NaCl; 2 g Na2HPO4; 2 g
NaHCO3; 20 g Na acetate; 200 g sucrose; and 15 g agar. The
medium was autoclaved at 115C for 15 minutes, and after
cooling to 55C, 200IE bacitracin was incorporated. Within
an hour, samples were transferred to a microbiology labo-
ratory, and glass beads were added to the Eppendorf tubes
containing dental plaque and vortexed for 1 minute at full
speed to homogenize the samples. Twenty microliters of
the homogenized suspension was plated on TYCSB, SDA,
and SBA plates. The SDA and SBA plates were incubated
aerobically at 37C for 48 hours, and the TYCSB plates were
incubated in an atmosphere of 7% CO2 at 37C for 5 days.
After incubation, colonies on the plates were counted, and
results are presented as colony-forming units (CFU)/mL.
Statistical analysis
Statistical analysis of the clinical and microbiological data
collected was performed using the statistical package,
SPSS version 16.0 (SPSS for Windows, Chicago, IL, USA). All
values were reported as the mean and standard deviation
(S.D.). Repeated-measures analysis of variance (ANOVA)
was used to evaluate the study data. Pearson rank corre-
lations were used to analyze correlations of clinical peri-
odontal variables and microbiologic parameters. Each point
on the graphs shows the ID number of the person whose
variable value is an outlier of the distribution. In all
statistical evaluations, 0.05 was taken as the cutoff for the
level of significance.
Results
All participants completed the study with no complications.
Results of full-mouth clinical indices from all groups are
presented in Table 1. There were no significant differences
in clinical parameters between groups at the baseline. PI
values ascertained on Days 0 and 4 were found toTable 1 Full-mouth PI, QPI, GI and PD values for all
groups at different time intervals.
Group Visit PIa QPIa GIa
0.2% CHX
nZ 12
Day 0 0.03 (0.02) 0.41 (0.10) 0.02 (0.02)
Day 4 0.49 (0.18) 0.66 (0.38) 0.42 (0.28)
2% CH
nZ 12
Day 0 0.03 (0.01) 0.83 (0.19) 0.02 (0.01)
Day 4 0.66 (0.17)b 0.87 (0.22)c 0.54 (0.27)
CHXþ CH
nZ 12
Day 0 0.06 (0.03) 0.41 (0.14) 0.04 (0.02)
Day 4 0.37 (0.13)b 0.50 (0.36)c 0.59 (0.31)
CHZ chitosan; CHXZ chlorhexidine; GIZ gingival index;
PIZ plaque index; QPIZQuigleyeHein plaque index.
a Normally distributed data are expressed as means (standard
deviations). Repeated ANOVA test for comparisons.
b PI: difference between CH and CHXþ CH groups was statis-
tically significant, PZ 0.019 (P< 0.05).
c QPI: difference between CH and CHXþ CH groups was
statistically significant, PZ 0.026 (P< 0.05).significantly differ (P< 0.05) in each group. The CHXþ CH
combination group showed the lowest PI scores on Day 4.
No significant differences in QPI scores were observed in
any groups during the experimental period. However, the
2% CH group showed higher QPI values on Days 0e4 than the
others groups. Variations in PI and QPI values on days 0e4
were found to significantly different between the 2% CH
and CHXþ CH groups (P< 0.05). In each group, full-mouth
GI scores showed significant differences between
measurements (P< 0.05). However, no significant differ-
ences were observed in GI values between groups at any
measurement time (P> 0.05). When comparing groups, GI
scores were higher in the CHXþ CH group than the others,
but this was not statistically significant.
For sample site clinical observations, changes in PI
scores of sampling sites are shown in Fig. 2. At sampling
sites, PI scores were observed to significantly differ in each
group at various time intervals (P< 0.001). On Day 4, higher
PI scores were obtained in both the 2% CH and CHXþ CH-
combination groups. However, these differences between
groups were not statistically significant (P> 0.05). GI scores
at sample sites at the measurement times are shown in
Fig. 3. Differences in GI scores were found to be significant
in each group (P< 0.001). However, the 2% CH group had
a higher GI score than the CHX and CHXþ CH combination
groups on Day 4. These differences were not statistically
significant (P> 0.05). Values of the QPI from sampling sites
are presented in Fig. 4. Significant differences were
observed in QPI values between Days 0 and 4 in each group
(P< 0.05). QPI scores were not found to significantly differFigure 2 The values of PI in sample sites for each group. The
data are expressed as means and standard deviations.
BZ baseline; CHZ chitosan; CHXZ chlorhexidine; CHXþ CHZ
chlorhexidineþ chitosan; PIZ plaque index. Difference
between B and Day 0 in each group was statistically significant
(P< 0.05). Difference between B and Day 4 in each group was
statistically significant (P< 0.05). Difference between Day
0 and Day 4 in each group was statistically significant
(P< 0.05). Difference between groups at time intervals was
not statistically significant (P> 0.05).
Figure 3 The values of GI in sample sites for each group. The
data are expressed as means and standard deviations.
BZ baseline; CHZ chitosan; CHXZ chlorhexidine; CHXþ CHZ
chlorhexidineþ chitosan; GIZ gingival index. Difference
between B and Day 0 in each group was statistically significant
(P< 0.05). Difference between B and Day 4 in each group was
statistically significant (P< 0.05). Difference between Day
0 and Day 4 in each group was statistically significant
(P< 0.05). Difference between groups at time intervals was
not statistically significant (P> 0.05). *Represents the samples
which are outliners in the dataset.
Figure 4 The values of QPI in sample sites for each group.
The data are expressed as means and standard deviations.
CHZ chitosan; CHXZ chlorhexidine; CHXþ CHZ chlorhex-
idineþ chitosan; QPIZQuigleyeHein plaque index. Difference
between Day 0 and Day 4 in each group was statistically
significant (P< 0.01). Difference between groups at time
intervals was not statistically significant (P> 0.05). *Repre-
sents the samples which are outliners in the dataset.
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than the CHXþ CH-combination group on Day 4 ( P> 0.05).
For microbiological observations, results from plaque
samples collected are presented in Figs. 5 and 6 for changes
in S. mutans and C. albicans levels, respectively. Changes in
S. mutans and C. albicans levels were statistically signifi-
cant in each group on Days 0 to 1 (P< 0.05), Days 0 to 2
(P< 0.05), and Days 0 to 4 (P< 0.001). When comparing the
three groups, a higher S. mutans amount was obtained in
the CHX group on Day 0, in the CHXþ CH combination group
on Days 0 and 1, and in 2% CH group on Day 0, whereas no
statistical differences were observed in S. mutans amounts
between groups at any time interval (P> 0.05). The lowest
C. albicans amounts were obtained in the CHX group for all
measurements, and the 2% CH group had a higher C. albi-
cans amount on Day 0. On all experiment days, the amount
of C. albicans was significantly reduced in all groups.
Differences between groups were found to be significant on
Day 0 (P< 0.001). No differences were observed among
all groups on Day 4. Enterococcus spp. was not found in
any clinical plaque samples during the experimental period.
No correlation was found between clinical indices and
S. mutans, C. albicans, or Enterococcus spp. in any group
during the experimental period. A positive correlation was
observed between PI and GI scores in the CHX (rZ 0.665,
P< 0.05), CHXþ CH (rZ 0.833, P< 0.05), and 2% CH
(rZ 0.928, P< 0.05) groups on Day 0 in experiment. No
correlation was found between clinical indices on Days
0 and 4 in any group.Figure 5 The values of SM in sample sites for each group.The
data are expressed as means and standard deviations.
CHZ chitosan; CHXZ chlorhexidine; CHXþ CHZ chlorhex-
idineþ chitosan; SMZ S. mutans. Difference between Day
0 and Day 1 in each group was statistically significant
(P< 0.05). Difference between Day 0 and Day 2 in each group
was statistically significant (P< 0.05). Difference between Day
0 and Day 4 in each group was statistically significant
(P< 0.001). Difference between groups at time intervals was
not statistically significant (P> 0.05). *Represents the samples
which are outliners in the dataset.
Figure 6 The values of CA in sample sites for each group.
The data are expressed as means and standard deviations.
CAZ C. albicans; CHZ chitosan; CHXZ chlorhexidine;
CHXþ CHZ chlorhexidineþ chitosan. Difference between Day
0 and Day 1 in each group was statistically significant
(P< 0.05). Difference between Day 0 and Day 2 in each group
was statistically significant (P< 0.05). Difference between Day
0 and Day 4 in each group was statistically significant
(P< 0.05). Difference between CHX and CH at time intervals
was statistically significant (P< 0.01). *Represents the samples
which are outliners in the dataset.
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The aim of this study was to evaluate and compare the
antiplaque effects of a 60 second rinse with 0.2% CHX and
the 2% CH/CHX combination during 4 days (96 hours) of
plaque accumulation.
Results of this study indicated that the mouth rinses we
evaluated demonstrated a range of inhibitory effects on the
test bacteria. These conclusions were supported by the
clinical parameters and microbiologic outcomes.
In the present study, when comparing gingival indices,
the lowest scores were obtained by rinsing with CHXþ CH
after 96 h of the plaque accumulation period (P< 0.001),
suggesting that the combination treatment offered a better
antiplaque effect than CHX alone. With regard to plaque
accumulation for 4 days, although the PI revealed that the
combination treatment provided a better antiplaque
activity, the difference was not significant. As expected,
for probing pocket depths, no significant alterations were
detected. This observation can be explained by the short
experimental period and patient selection. However, when
the GI scores were compared, the best antiplaque effect
was obtained with the use of CHXþ CH combination
treatment (P< 0.001).
Several in vitro and in vivo studies have proved the long-
term efficacy of CHX mouth rinses,3,34,35 and 0.2% CHX has
been accepted as the gold standard as it shows bacterio-
static action for 12 hours.36 In order to reduce local side
effects of CHX, the use of CHX mouth rinses of lowerconcentrations was considered, and decreased side effects
were reported.17,18 As for plaque inhibition, no differences
were observed between 0.1%, 0.12%, and 0.2% CHX mouth
rinses.13,37 However, it has been suggested in one study
that evaluated 0.1% CHX mouth rinse, that the degree of
CHX inactivation was caused by its formulation.38 Concen-
tration of 0.12% CHX appeared to be as effective as 0.2%, if
the volume of the rinse was increased to 15 mL.4 The
optimal dose of CHX is generally considered to be a regime
of 20 mg twice a day,18,39 which balances efficacy against
local side effects and user acceptability. In order to reach
an optimal dose, we used 10 mL of 0.2% CHX twice a day in
our study design. In a recent study. Charles et al7 evaluated
the antiplaque effectiveness of a CHX and essential oil
mouth rinse. All participants used one of the two mouth
rinses as an adjunct to their usual mechanical oral hygiene
procedures for 6 months. After 6 months, both of the mouth
rinses showed comparable antiplaque activities. Similarly in
this study, we compared 0.2% CHX to 2% CH, and after 4
days of a plaque accumulation period, no significant
differences were observed with regard to PIs or GIs, sug-
gesting that CH may be an alternative chemical agent for
managing patients who show side effects associated with
CHX. These results might be explained by the favorable
bioadhesive properties of CH and its good retention on oral
surfaces.
CHX was used in different concentrations and in
different formulations. Van Strydonck et al40 evaluated two
commercial CHX mouth rinses (0.12% CHX in a non-alcohol
base with 0.05% cetyl pyridinium chloride (Cpc) vs. 0.2%
CHX in an alcohol base). After 3 days of a plaque accumu-
lation period, there was no significant difference in plaque
accumulation between the two groups. In our study
comparing the antiplaque effects, the combination of
CHXþ CH was slightly more effective than either CHX or CH
alone, but the difference was not significant. However with
regard to GI scores, the combination of CHXþ CH showed
the best antiplaque effect, and the difference was statis-
tically significant.
So far, there have only been a few studies reporting the
effects CH and CHX combinations on oral microorganisms.
Giunchedi et al20 evaluated CHX buccal tablets prepared
using drug-loaded CH microspheres. Combining CH micro-
spheres as controlled drug delivery systems with CHX not
only prolonged the release of the drug in the oral cavity but
also improved the antimicrobial activity of CHX. In a recent
study, Decker et al21 evaluated CHX on plaque combination
to improve antiplaque strategies. In that study, CHX (0.1%)
was used as the positive control, saline was the negative
control, and two CH derivates together with their CHX
combination were attached to Streptococci sanguis for 2
minutes. In their results, the CHXþ CH combination was
stronger than CHX alone, because it united the bioadhesive
properties of CH with the antibacterial activity of CHX
which resulted synergistically in a superior antiplaque
effect to CHX alone. In our study, we evaluated S. mutans
levels during 96 h of a non-brushing period. The results
from plaque samples collected revealed that the reduction
in S. mutans was more pronounced when using CHXþ CH,
but this reduction did not significantly differ when the
groups were compared. On Day 1, C. albicans was signifi-
cantly lower in the CHX group compared to the 2% CH
348 A. Uraz et algroup. During the experimental period, the CHXþ CH
combination showed higher C. albicans levels; this differ-
ence did not reach statistical significance.
This 4-day randomized clinical trial demonstrated that
all of the treatment modalities had comparable antiplaque
activities. The promising outcomes of this study could allow
CH to be considered as a mouth rinse either alone or in
combination with CHX. The precise antibacterial mecha-
nism of CH is still unknown. Further studies will help opti-
mize CH formulations either alone or combined with other
antiplaque agents.Acknowledgments
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